InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated:15 August 2023

ADVANTIG-02: This Phase III trial is trying to understand effective different combinations of targeted and immunotherapies (Tislelizumab, Ociperlimab, and Pembrolizumab) are in people with non-small cell lung cancerA Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Clinical summary

Summary

This is a randomised trial with three arms. In Arm A (Experimental), participants will receive tislelizumab 200 milligrams (mg) intravenously followed by ociperlimab 900 mg intravenously once every 3 weeks. In Arm B (Active comparator), Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks. In Arm C (Placebo comparator), Participants will receive tislelizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.

Treatment Type

Radiotherapy

Age

People18+

Phase

III

Trial Acronym

ADVANTIG-02

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

  • NCT04746924
  • BEIGENE, BGB-A317-A1217-302, TIGIT-302, CT1363, BGB-302

Commercial Sponsor

BeiGene Australia Pty Ltd

Scientific Title

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Eligibility

Inclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.

Exclusion

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had a certain type of treatment or surgical procedure.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

+ Show non-recruiting hospitals

Closed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more